Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer
Year: 2019
Type: conference-abstract
Source: Cancer Research
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: atezolizumab, nab-paclitaxel, triple-negative breast cancer, metastatic breast cancer, locally advanced breast cancer, PD-L1 expression, tumor-infiltrating immune cells, stromal tumor-infiltrating lymphocytes, immunological markers, predictive biomarkers, first-line therapy, progression-free survival, overall survival, BRCA1/2 mutation status, HER2
Open Access status: closed
OpenAlex ID: W2944446380
